Huang Yecai, Feng Mei, Yang Xuegang, Zhou Jie, Li Lu, Xu Ke, Xu Guohui, Lang Jinyi
School of Medicine, University of Electronic Science and Technology of China , Chengdu, People's Republic of China.
Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, People's Republic of China.
Cancer Manag Res. 2020 May 6;12:3107-3116. doi: 10.2147/CMAR.S239033. eCollection 2020.
Nasopharyngeal carcinoma (NPC) is one of the most highly radiosensitive malignancies; however, some locally advanced NPC patients experienced local recurrence even though they received aggressive treatment regimens. Defining the tumor volume precisely is important to escalate the total dose required for the primary tumor. In this study, we aimed to investigate the feasibility and efficacy of dose escalation guided by DW-MRI in patients with locally advanced NPC.
A total of 230 patients with locally advanced NPC treated with intensive modulated radiotherapy (IMRT) at Sichuan Cancer Hospital between January 2010 and January 2015 were enrolled in this retrospective study. All the patients were treated with all-course of simultaneous integrated boost-IMRT. DW-MRI-guided dose escalation with 2.2-2.5 Gy/F, qd for 1-3 days or 1.2-1.5 Gy/F, bid for 1-3 days were prescribed to 123 patients. Survival and complication of the patients were evaluated, and multivariate analysis was performed.
The median follow-up of patients in the DW-MRI-guided dose-escalation group and the conventional group was 48 months (range 8-88 months) and 52 months (range 6-90 months), respectively. The 5-year overall survival rate, distant metastasis-free survival rate, progression-free survival, and local recurrence-free survival (LRFS) of patients in the dose-escalation group and the conventional group were 88% vs 82.5% ( = 0.244), 86.1% vs 83.3% ( = 0.741), 82.2% vs 76.6% ( = 0.286), and 89.1% vs 80.1% ( = 0.029), respectively. Multivariate analysis showed that dose escalation was independent prognostic factor for LRFS (HR 0.386, 95% CI 0.163-0.909, = 0.03).
DW-MRI-guided dose escalation is a feasible strategy to improve local control of patients with locally advanced NPC. The treatment-related complications are tolerable.
鼻咽癌(NPC)是放射敏感性最高的恶性肿瘤之一;然而,一些局部晚期鼻咽癌患者即使接受了积极的治疗方案仍会出现局部复发。精确界定肿瘤体积对于提高原发肿瘤所需的总剂量很重要。在本研究中,我们旨在探讨磁共振扩散加权成像(DW-MRI)引导下剂量递增在局部晚期鼻咽癌患者中的可行性和疗效。
本回顾性研究纳入了2010年1月至2015年1月期间在四川省肿瘤医院接受调强放疗(IMRT)的230例局部晚期鼻咽癌患者。所有患者均接受全程同步整合加量IMRT治疗。123例患者接受了DW-MRI引导下的剂量递增,剂量为2.2 - 2.5 Gy/次,每日1次,共1 - 3天,或1.2 - 1.5 Gy/次,每日2次,共1 - 3天。评估患者的生存情况和并发症,并进行多因素分析。
DW-MRI引导下剂量递增组和传统组患者的中位随访时间分别为48个月(范围8 - 88个月)和52个月(范围6 - 90个月)。剂量递增组和传统组患者的5年总生存率、无远处转移生存率、无进展生存率和无局部复发生存率(LRFS)分别为88%对82.5%(P = 0.244)、86.1%对83.3%(P = 0.741)、82.2%对76.6%(P = 0.286)和89.1%对80.1%(P = 0.029)。多因素分析显示,剂量递增是LRFS的独立预后因素(HR 0.386,95%CI 0.163 - 0.909,P = 0.03)。
DW-MRI引导下的剂量递增是提高局部晚期鼻咽癌患者局部控制的可行策略。治疗相关并发症是可耐受的。